| Document |
Document Title |
|
WO/2012/127176A1 |
The present invention relates to novel neurosteroids, especially derivatives of allopregnanolone and of epiallopregnanolone of formula (I) and the uses thereof as medicament for the treatment of neuropathologies, in particular neuropathi...
|
|
WO/2012/100018A1 |
Stabilized benzyl phosphonic acid and naphthyl phosphonic acid analog compounds are effective in inhibiting the activity of autotaxin.
|
|
WO/2012/079275A1 |
Provided is a method for preparing fluticasone furoate (fluoromethyl 6α,9α-difluoro-11β-hydroxy-16a-methyl-17α-[(2-furoyl)oxy
]-3-one androsta-1,4-diene-17β-thiocarboxylate) represented by Formula I. The method comprises: 1) forming...
|
|
WO/2012/068832A1 |
Provided is a method for preparing mogroside IV, which comprises hydrolyzing mogroside V, Momordica grosvenori fruits, or extracts of Momordica grosvenori fruits containing mogroside V with β-glucosidase. The content of mogroside IV in ...
|
|
WO/2012/027957A1 |
Bufalin derivatives of formula I and the pharmaceutical compositions thereof are provided, wherein the radicals have the meanings as defined in the invention. The use of these derivatives is also provided.
|
|
WO/2011/077800A1 |
A neutral fat level control agent, a cholesterol level control agent, a free fatty acid level control agent and an anti-obesity agent, each characterized by comprising at least one of protopanaxatriol, panaxatriol, protopanaxadiol and pa...
|
|
WO/2011/073419A1 |
The present invention relates to a compound of formula (I) for its use for reversing or inhibiting multidrug resistance.
|
|
WO/2011/036557A1 |
Compositions, methods and compounds useful for enhancing the uptake of a lipid particle b\ a cell are described In particular embodiments, the methods of the invention include contacting a cell with a lipid particle and a compound that b...
|
|
WO/2011/010364A1 |
Disclosed is a novel compound having a neurite-outgrowing activity and is therefore useful for the prevention or treatment of neurodegenerative diseases. Specifically disclosed is a compound represented by formula (I) [wherein X represen...
|
|
WO/2011/002033A1 |
A glucose metabolism-improving agent having an activity of suppressing the increase in an after-meal glucose level, an activity of decreasing a fasting glucose level, an activity of regulating a glucose metabolism-related measure in seru...
|
|
WO/2010/102952A1 |
The present invention relates to a process of reducing the content of steryl glycoside in a bio-diesel composition which comprises a step of contacting the composition with an enzyme being capable of acylating the steryl glycoside.
|
|
WO/2010/095741A1 |
Disclosed is a novel steroid derivative which is expected to exhibit an NGF activity. Specifically disclosed is a compound represented by formula (A) or (B). (In the formulae (A) and (B), n represents 1 or 2.)
|
|
WO/2010/058794A1 |
Disclosed is a highly safe antioxidant which suppress oxidation of biological components, particularly oxidation of lipids, and can be used as a pharmaceutical product, food, drink, food additive, external preparation for the skin and th...
|
|
WO/2010/048710A1 |
The invention relates to compositions for use in animal models of neurodegenerative disease and methods therefor. More particularly, the invention relates to the use of neurotoxic sterol glycosides or neurotoxic glycolipids, or combinati...
|
|
WO/2010/041681A1 |
Provided is a novel compound which is a sominone derivative represented by formula (1) or a salt thereof and which is useful as an agent for the prevention and treatment of neurological disease.
|
|
WO/2010/029915A1 |
Disclosed is a simple method for producing a plant containing sapogenin, which contains a large quantity of sapogenin and has outstanding taste and safety, using a plant containing saponin as the raw material. The method for producing a ...
|
|
WO/2010/027992A1 |
A method of preventing preeclampsia including administering to a patient during an early stage of pregnancy a prophylactically-effective amount of resibufogenin. The administration of resibufogenin is periodically repeated. The method se...
|
|
WO/2009/135449A1 |
The invention relates to novel ligands of the estrogen receptors α and β of general formula (II), which are useful as active substance of pharmaceuticals, for example pharmaceutical compositions useful for hormone replacement therapy, ...
|
|
WO/2009/106360A2 |
The present invention relates to a method for purifying biodiesel, biodiesel precursors, or the mixtures thereof, which contain at least one glycoside, wherein biodiesel or a biodiesel precursor or a mixture thereof is incubated with at ...
|
|
WO/2009/024103A2 |
The present invention relates to natural brassinosteroids of general formula (I), wherein R is CH2 or O-CH2 group, R2 is hydrogen or hydroxyl, R3 is hydroxyl, R24 is alkyl or alkenyl, which are selected from the group consisting of methy...
|
|
WO/2009/023975A2 |
Provided is the novel sweetener and sweetness enhancer iso-mogroside V, compositions comprising the sweetener/sweetness enhancer for use in consumables (food products and products place in the oral cavity including mouth wash and other d...
|
|
WO/2008/136199A1 |
A process for producing a compound represented by the following formula (2): (2) (wherein R1 means hydrogen, methyl, or CH2OH; R2 means hydrogen or methyl; R3 means hydrogen or hydroxy; R4 means hydrogen or hydroxy; and R5 means hydroxy,...
|
|
WO/2008/127381A2 |
This disclosure provides improved derivatives of artemisinin; pharamaceutical compositions containing these compounds; methods for preparing these compounds and compositions; methods of using these compounds and compositions for preventi...
|
|
WO/2008/109936A1 |
The present invention provides a compound of Formula I, pharmaceutical compositions and methods of use thereof.
|
|
WO/2008/102716A1 |
Disclosed is an agent for treatment of ADHD-related diseases, which contains a compound represented by the formula (1) below or at least one pharmaceutically acceptable salt thereof as an active ingredient. (1) (In the formula, R1 and R2...
|
|
WO/2008/078362A1 |
An antitumor agent containing at least one compound selected from the group consisting of nerigoside, oleandrigenin, sarmentoside, oleaside A, oleandrin, 8β-hydroxy odoroside A, narciclasine, trans-dihydronarciclasine and bisdeoxynarcic...
|
|
WO/2008/047149A1 |
A stable aqueous pharmaceutical composition comprising anhydrous mometasone furoate and a pharmaceutically acceptable carrier.
|
|
WO/2008/028584A1 |
The invention relates to preparations for oral administration, containing (a) physiologically active fatty acids with 16 to 26 carbon atoms and 2 to 6 double bonds, the esters or glycerides thereof and (b) Hoodia extracts or the steroid ...
|
|
WO/2008/026300A1 |
The object is to provide a novel therapeutic agent for malignant tumor. Disclosed is a therapeutic agent for malignant tumor or an apoptosis inducer which comprises a compound selected from epoxyazadiradione, gedunin, 17-epi-17-hydroxyaz...
|
|
WO/2008/022875A1 |
Process for preparing a composition comprising one or more steroidal glycosides, comprising the steps of: (a) harvesting Hoodia plants, (b) cutting up the harvested plants, (c) drying the cut plants, whereby exposure to UV light during t...
|
|
WO/2007/070598A9 |
The present invention discloses compounds of formula (I): which exhibit antiviral properties. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject in...
|
|
WO/2007/112573A1 |
The present invention describes nitrate esters of sterols and stanols that bear an ascrobic acid moiety and a phosphate linking group, as well as pharmaceutically acceptable salts and stereoisomers thereof The invention also provides nov...
|
|
WO/2007/115187A2 |
A platform service that is used by an application may be linked to an advertising service. A cost of using the platform service may be reduced based on the linking.
|
|
WO/2007/094166A1 |
A drug for recovery from a spinal cord injury, characterized by containing as an active ingredient a compound represented by the following structural formula (1) or a pharmaceutically acceptable salt thereof: Structural formula 1 (wherei...
|
|
WO/2007/080951A1 |
The invention provides a novel process for the production of steroids, namely, a process for the production of 5β-3,7 -dioxocholanoic acid or ester derivatives thereof which comprises using as the raw material a sterol having double bon...
|
|
WO/2007/076163A2 |
The present disclosure concerns a process for removing steryl glycosides or monoacylglycerols from biodiesel by contact of the biodiesel with an absorbant, or filter aid. Treated biodiesel as well as steryl glycosides derived from biodie...
|
|
WO/2007/060206A2 |
New crystalline forms of 17β-(3-Furyl)-5-βandrostane-3β,14β,17α-triol are described together with pharmaceutical composition containing the same and methods for their preparation. In particular new Forms B, C, D, E and H are here de...
|
|
WO/2007/056326A2 |
The invention relates to a double-stranded ribonucleic acid (dsRNA) for inhibiting the expression of the Nav1.8 gene (Nav1.8 gene), comprising an antisense strand having a nucleotide sequence which is less that 25 nucleotides in length a...
|
|
WO/2007/043302A1 |
Disclosed is a pharmaceutical or beverage/food which can inhibit the production of an adipocytokine, particularly an adipocytokine that can induce the resistance to insulin, to thereby prevent or ameliorate the occurrence of a morbid con...
|
|
WO/2007/043305A1 |
Disclosed is a pharmaceutical or beverage/food which can inhibit the production of an adipocytokine, particularly an adipocytokine that can induce the resistance to insulin, to thereby prevent or ameliorate the occurrence of a morbid con...
|
|
WO/2007/039346A2 |
A photoresist composition including a polymer, a photoacid generator and a dissolution modification agent, a method of forming an image using the photoresist composition and the dissolution modification agent composition. The dissolution...
|
|
WO/2007/034851A1 |
Disclosed is a pharmaceutical or beverage/food which can reduce the fat accumulated in the abdominal cavity and can prevent or ameliorate visceral obesity which is believed to be the primary cause of metabolic syndrome. The pharmaceutica...
|
|
WO/2007/006208A1 |
Medicinal composition containing ginseng secondary glycosides, its preparation method and application. The present composition contains mainly, as active ingredients, the ginsenoside with protopanoxadiol as aglucone (ginsenoside Rg3) and...
|
|
WO/2006/124012A2 |
The present invention provides compositions and methods for treating and preventing Alzheimer's disease by administering to a subject an effective amount of a dammarane or ginsenoside compound. The invention also provides compositions an...
|
|
WO/2006/123464A1 |
Use of 3-O-β-D-glucopyranosyl-4-methylergost-7-en-3-ol or compositions which consist of extracts of liliaceous plants or fractions thereof containing 3-O-β-D-glucopyranosyl-4-methyl- ergost-7-en-3-ol and contain the compound in amounts...
|
|
WO/2006/113495A2 |
The present invention relates to a series of dicarboxylic acid ester derivatives of ginsenosides such as succinate and glutarate derivatives of 20-O-β-D- glucopyranosyl-protopanaxadiol (compound K, abbreviated as CK), preparation thereo...
|
|
WO/2006/110810A2 |
The present invention relates to crystalline polymorphs of 3-O-(3',3'-dimethylsuccinyl)betulinic acid di-N-methyl-D-glucamine salt ("DSB•2NMG)"), pharmaceutical compositions of the same and use of the same as an active pharmaceutical a...
|
|
WO/2006/086377A2 |
The invention relates to a multiplex real-time RT-PCR assay with a heterologous internal control system (i.e., EGFP-RNA) for the simple and fast diagnosis of classical swine fever virus (CSFV). Primers and FAM-labeled TaqMan probes, spec...
|
|
WO/2006/052717A2 |
A glucuronide metabolite of tigecycline, and its corresponding epimer, have been identified in humans treated with tigecycline. Mass spectral data have been used to identify these structures.
|
|
WO/2006/045171A2 |
The present invention refers to a process to obtain ergostane derivative dry steroids, such as physalins, including steps of: (a) grinding of dried parts of plant (s) from the Solanaceae species; (b) treatment of the said plant (s)' part...
|
